Pipeline

Curatis identifies potential drug candidates in indications with high unmet medical need via its extensive network within the scientific and medical community and the biotech/pharmaceutical industry. Curatis significantly invests in its development projects. Curatis' strategy is to identify compounds for which safety and clinical efficacy data already exist, enabling faster development with lower risk and investment through to commercialization.

Partnerships for developing novel medicines

To ensure efficient and state-of-the art developments of its pipeline projects, Curatis maintains co-development partnerships with other innovative small and medium-sized biotech/pharmaceutical companies, and also with best-practice contract research and manufacturing organisations. Curatis is looking for larger pharmaceutical companies for licensing or co-development arrangements for the late stage clinical development of its pipeline projects.

For more information, please contact us at info(at)curatis.com